Meehyun Ko

Songnam, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Host-Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules.

Host-Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 10, 2025

Broad-Spectrum Antiviral Agents against SARS-CoV-2 Variants Inhibit the Conserved Viral Protein Nsp1-RNA Interaction.

Broad-Spectrum Antiviral Agents against SARS-CoV-2 Variants Inhibit the Conserved Viral Protein Nsp1-RNA Interaction.

Journal: Angewandte Chemie (International ed. in English)

Published: March 20, 2024

Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.

Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.

Journal: Journal of medical virology

Published: March 23, 2023

Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern.

Lancemaside A from Codonopsis lanceolata: Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern.

Journal: Antimicrobial agents and chemotherapy

Published: November 14, 2022

Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants.

Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants.

Journal: iScience

Published: May 18, 2022

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).

Journal: Microbiology spectrum

Published: August 11, 2021

Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals.

Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals.

Journal: Briefings in bioinformatics

Published: July 10, 2021

Published Anti-SARS-CoV-2 In Vitro Hits Share Common Mechanisms of Action that Synergize with Antivirals.

Published Anti-SARS-CoV-2 In Vitro Hits Share Common Mechanisms of Action that Synergize with Antivirals.

Journal: bioRxiv : the preprint server for biology

Published: March 10, 2021

Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.

Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.

Journal: Viruses

Published: January 19, 2021

Sex differences in viral entry protein expression and host transcript responses to SARS-CoV-2.

Sex differences in viral entry protein expression and host transcript responses to SARS-CoV-2.

Journal: Research square

Published: November 11, 2020

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.

Journal: Journal of medical virology

Published: June 27, 2020

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Journal: Antimicrobial agents and chemotherapy

Published: April 27, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026